In Phase C, individuals will get ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment right until illness progression or even the participants are not able to tolerate the study drugs. Ubiquitin-similar proteins that regulate the stability of key Tremendous enhancer-mediated proteins https://clinicaltrialrecruitmentf81357.blogripley.com/32552015/the-fact-about-abbv-744-in-combination-with-immunotherapy-that-no-one-is-suggesting